Proteinuria

Adults with class II to III obesity may have an increased risk for poor cardiac outcomes but not kidney risk after adjusting for potential confounders, according to multicenter data.

LONG BEACH, Calif. — Iptacopan may be superior to placebo in reducing proteinuria at 9 months, with early onset and effect consistency, according to data presented at the National Kidney Foundation Spring Clinical Meetings, here.

The European Commission has granted conditional marketing authorization to Filspari, Travere Therapeutics and CSL Vifor announced in a press release.

Researchers identified multiple proteins linked to a higher risk of major cardiovascular events in a study that analyzed blood tests from older adults with kidney disease.

A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with chronic kidney disease, according to a press release.

Healio has compiled a list of its most-read nephrology care news in 2023.

The FDA has granted full approval for Tarpeyo delayed-release capsules to reduce the loss of kidney function in adults with IgA nephropathy who are at risk for disease progression, according to a press release.

Elevated resting heart rate may be a novel risk factor for end-stage renal disease, independent from other traditional risk factors, according to a study published in the Journal of the American Heart Association.

PHILADELPHIA — The case of a 29-year-old woman with chronic kidney disease presented at ASN Kidney Week highlighted the need for better health care education to help patients understand the risks and consequences of their disease.

PHILADELPHIA — Sparsentan was shown to be safe and well-tolerated, and reduced proteinuria in adults with IgA nephropathy, according to studies presented at ASN Kidney Week.